On the basis of this relationship and on IL-10's known anti-inflammatory properties, Nakagome et al. used intratracheal bleomycin to model IPF, then administered intravenous IL-10 plasmid 2 weeks later, mimicking the treatment of established or chronic disease. Here, IL10 is linked to idiopathic pulmonary fibrosis.